TFFP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TFFP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. TFF Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.044. TFF Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-29), TFF Pharmaceuticals's share price is $0.065. TFF Pharmaceuticals's Median PS Value is $0.00. Therefore, TFF Pharmaceuticals's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for TFF Pharmaceuticals's Median PS Value or its related term are showing as below:
The historical data trend for TFF Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TFF Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
TFF Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, TFF Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where TFF Pharmaceuticals's Price-to-Median-PS-Value falls into.
TFF Pharmaceuticals's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0.044 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
TFF Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.044.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TFF Pharmaceuticals (NAS:TFFP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
TFF Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.065 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of TFF Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Carlson Capital L P | 10 percent owner | 2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201 |
Clint Duane Carlson | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201 |
Zamaneh Mikhak | officer: Chief Medical Officer | 1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107 |
Robert S Mills | director | 8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812 |
Kirk Allen Coleman | officer: CFO, Secretary, and Treasurer | 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Asgard Investment Corp. Ii | 10 percent owner | 2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201 |
Double Black Diamond Offshore Ltd | 10 percent owner | CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205 |
Harlan F Weisman | director | C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Brandi Roberts | director | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Fletcher Aaron G.l. | director | 40 GUEST STREET, BOSTON MA 02135 |
Randy H Thurman | director | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Glenn R. Mattes | director, officer: President and CEO | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Malcolm Fairbairn | director | C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563 |
Lung Therapeutics, Inc. | 10 percent owner | P.O. BOX 150183, AUSTIN TX 78715 |
From GuruFocus
By Marketwired • 09-26-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 05-14-2024
By PRNewswire • 02-06-2025
By Marketwired • 08-14-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 05-15-2024
By Marketwired • 09-10-2024
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.